Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function

Eur J Clin Pharmacol. 1989;37(2):151-3. doi: 10.1007/BF00558223.


The effect of imipramine on symptomatic peripheral diabetic neuropathy in 9 patients was examined in a double-blind cross-over study against placebo. The dose of imipramine was adjusted to yield optimal plasma levels of imipramine plus desipramine of 300-750 nM. Imipramine had a clear beneificial effect on the symptoms of the neuropathy, whereas no changes in a range of neurophysiological measurement was detected. Despite some adverse effects, especially of an anticholinergic nature, the patients generally preferred imipramine to placebo.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Autonomic Nervous System / drug effects*
  • Diabetic Neuropathies / drug therapy*
  • Female
  • Humans
  • Imipramine / adverse effects
  • Imipramine / blood
  • Imipramine / therapeutic use*
  • Male
  • Middle Aged
  • Peripheral Nerves / drug effects*


  • Imipramine